Paysign(US:PAYS)2021-08-11 02:25Financial Data and Key Metrics Changes - Total net revenue for Q2 2021 was $6.7 million, a year-over-year increase of 3.2% [7] - Gross margin for the quarter was 47.4%, aided by the end of one pharmaceutical program [17] - Net loss for the quarter was $932,000, with adjusted EBITDA at $219,000, indicating near breakeven performance [18] - Restricted cash grew to $65.8 million during the quarter [18] - Full year revenue guidance is expected to be in the range of $29 million to $32 million, reflecting growth of 20% to 32% [26] Business Line Data and Key Metrics Changes - Plasma revenue accounted for $5.9 million or 89% of total revenues, with a year-over-year increase of $1.4 million [17][19] - Pharma revenue decreased to $641,000, down $1.1 million compared to Q2 2020, primarily due to program terminations [21] - Average revenue per month per plasma center was $5,633, with a potential increase to $6,138 if excluding April [19] - The company onboarded 13 additional plasma centers, bringing the total to 356 [10] Market Data and Key Metrics Changes - Total gross funds loaded increased by 34.7% year-over-year, while it decreased by 10.9% from the previous quarter due to seasonality [8] - Purchase volume increased by 44.5% compared to the year-ago period [18] Company Strategy and Development Direction - The company is focusing on diversifying its business and investing for long-term growth, particularly in the patient affordability space [11] - New copay programs are being launched, with five additional programs expected to launch by the end of 2021 [11][22] - The leadership team has been strengthened with new appointments in key positions [12][13] Management's Comments on Operating Environment and Future Outlook - Management noted improving trends in financial results as pandemic-related stimulus measures ended, with expectations for continued improvement [14] - The outlook presumes no re-entry into lockdowns and a recovery in the plasma business as unemployment subsidies end [27] Other Important Information - The company exited the quarter with $6.6 million in unrestricted cash and zero debt [25] - Operating expenses for the full year are expected to increase modestly to $18 million to $18.5 million [27] Q&A Session Summary - No specific questions or answers were documented in the provided content, indicating a conclusion to the call without detailed Q&A interactions [29][30]